X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
BW-1019, an intranasal COVID-19 booster, elicits mucosal immunity, stopping spread at the entry of the virus and, provided protection and boosted immune response when administered following an intramuscular vaccine series in preclinical studies.
Lead Product(s): BW-1019
Therapeutic Area: Infections and Infectious Diseases Product Name: BW-1019
Highest Development Status: PreclinicalProduct Type: Vaccine
Recipient: BlueWillow Biologics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2022
Details:
The results from study served as basis for immunobriding that gives MVC-COV1901 vaccine's Emergency Use Authorization in Taiwan and can support the advancement in subsequent developments.MVC-COV1901 vaccine involves molecular modifications to S-2P pre-fusion spike protein.
Lead Product(s): Recombinant S-2P antigen,CpG 1018,Aluminum hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: MVC-COV1901
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2021
Details:
First participant has been dosed in the Phase 2 clinical trial evaluating MVC’s COVID-19 vaccine candidate, MVC-COV1901. MVC-COV1901 is a subunit vaccine with recombinant S-2P antigen adjuvanted with CpG 1018 supplied by Dynavax.
Lead Product(s): Recombinant S-2P antigen,CpG 1018,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: MVC-COV1901
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Dynavax Technologies
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2021
Details:
Preclinical research demonstrated that BlueWillow’s nasal vaccine adjuvant combined with Medigen’s S-2P spike protein resulted in an extremely high neutralizing antibody response, as well as a superior IgA response in both serum and lung secretions samples in mice.
Lead Product(s): S-2P-NE-01
Therapeutic Area: Infections and Infectious Diseases Product Name: S-2P-NE-01
Highest Development Status: PreclinicalProduct Type: Vaccine
Recipient: BlueWillow Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 10, 2020
Details:
The first participant in MVC's Phase 1 clinical trial was dosed with MVC's COVID-19 vaccine combined with Dynavax's CpG 1018 adjuvant at National Taiwan University Hospital in early October.
Lead Product(s): S-2P vaccine,CpG 1018
Therapeutic Area: Infections and Infectious Diseases Product Name: S-2P vaccine
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Dynavax Technologies
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2020
Details:
The partners will leverage Medigen’s stable prefusion form of the SARS-CoV2 recombinant spike protein in combination with Dynavax’s advanced adjuvant CpG 1018.
Lead Product(s): COVID-19 adjuvanted vaccine,CpG 1018
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Dynavax Technologies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 23, 2020
Details:
Medigen signed an agreement with the NIH allowing it to obtain the candidate vaccine virus for potential use in humans to jump-start candidate vaccine development for Covid-19 in Taiwan.
Lead Product(s): Covid-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 17, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
